| Date Filed | Type | Description |
| 06/16/2023 |
4
| Sandoval Elisabeth (Director) has filed a Form 4 on PROCEPT BioRobotics Corp|
Txns:
| Granted 2,711 shares
@ $0
Granted 4,865 options to buy
@ $35.09, valued at
$170.7k
|
|
| 06/08/2023 |
4
| Sandoval Elisabeth (Director) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 10,000 options to buy
@ $26.99, valued at
$269.9k
Disposed/sold 20,000 options to buy
@ $4.6, valued at
$92k
Disposed/sold 30,000 options to buy
@ $3.46, valued at
$103.8k
Disposed/sold 14,893 options to buy
@ $4.56, valued at
$67.9k
|
|
| 08/12/2022 |
4
| Sandoval Elisabeth (Director) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Granted 20,500 options
@ $0.312, valued at
$6.4k
|
|
| 06/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/25/2021 |
4
| Sandoval Elisabeth (Director) has filed a Form 4 on PROCEPT BioRobotics Corp|
Txns:
| Granted 4,935 shares
@ $40.46, valued at
$199.7k
|
|
| 07/20/2021 |
4
| Sandoval Elisabeth (Director) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Granted 20,500 options
@ $2.75, valued at
$56.4k
|
|
| 04/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/07/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/07/2020 |
4
| Sandoval Elisabeth (Director) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.|
Txns:
| Granted 20,000 options to buy
@ $4.6, valued at
$92k
|
|
| 08/05/2020 |
4
| Sandoval Elisabeth (Director) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Granted 22,500 options
@ $1.72, valued at
$38.7k
|
|
| 06/16/2020 |
4
| Sandoval Elisabeth (Director) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.|
Txns:
| Granted 10,000 options to buy
@ $26.99, valued at
$269.9k
|
|
| 03/23/2020 |
4
| Sandoval Elisabeth (Director) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Granted 45,000 options
@ $2.67, valued at
$120.2k
|
|
| 09/12/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/27/2019 |
4
| Sandoval Elisabeth (Director) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Granted 11,645 options
@ $6.02, valued at
$70.1k
|
|
| 03/21/2019 |
4
| Sandoval Elisabeth (Director) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Granted 33,355 options
@ $8.24, valued at
$274.8k
|
|
| 03/21/2019 |
3
| Sandoval Elisabeth (Director) has filed a Form 3 on Menlo Therapeutics Inc. |
| 02/21/2018 |
4
| Sandoval Elisabeth (CCO & EVP, Corporate Strategy) has filed a Form 4 on ALDER BIOPHARMACEUTICALS INC|
Txns:
| Granted 60,000 options to buy
@ $13.55, valued at
$813k
|
|
| 12/21/2017 |
4
| Sandoval Elisabeth (Chief Commercial Officer) has filed a Form 4 on ALDER BIOPHARMACEUTICALS INC|
Txns:
| Granted 150,000 options to buy
@ $10.95, valued at
$1.6M
|
|
| 01/31/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 10/07/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 09/08/2016 |
3
| Sandoval Elisabeth (Chief Commercial Officer) has filed a Form 3 on ALDER BIOPHARMACEUTICALS INC |